{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["478(5)"],"submitter":["Mascolo M"],"funding":["Università degli Studi di Napoli Federico II"],"pubmed_abstract":["Mycosis fungoides (MF) represents the most common type of cutaneous lymphoma. In the majority of patients, the disease has a slow evolution and a protracted course; however, a subset of patients shows poor oncologic outcomes. Unfortunately, there are no reliable prognostic markers for MF, and the currently available treatments are only effective in a minority of patients. This study aimed to evaluate the expression and clinical significance of PARP-1 and CAF-1/p60 in MF. Sixty-four MF representatives of the different stages of disease were assessed by immunohistochemistry for PARP-1 and CAF-1/p60. The association of PARP-1 and CAF-1/p60 with the MF stage and outcome was assessed by using Fisher's exact test and Kaplan-Meier survival analysis with the Log-rank test; a p value < 0.05 was con"],"journal":["Virchows Archiv : an international journal of pathology"],"pagination":["961-968"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8099834"],"repository":["biostudies-literature"],"pubmed_title":["Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides."],"pmcid":["PMC8099834"],"pubmed_authors":["Russo D","Pane F","Varricchio S","Sabattini E","Travaglino A","Bertuzzi C","Pileri A","Agostinelli C","Mascolo M","Baldo A","Staibano S","Picardi M"],"additional_accession":[]},"is_claimable":false,"name":"Role of chromatin assembly factor-1/p60 and poly [ADP-ribose] polymerase 1 in mycosis fungoides.","description":"Mycosis fungoides (MF) represents the most common type of cutaneous lymphoma. In the majority of patients, the disease has a slow evolution and a protracted course; however, a subset of patients shows poor oncologic outcomes. Unfortunately, there are no reliable prognostic markers for MF, and the currently available treatments are only effective in a minority of patients. This study aimed to evaluate the expression and clinical significance of PARP-1 and CAF-1/p60 in MF. Sixty-four MF representatives of the different stages of disease were assessed by immunohistochemistry for PARP-1 and CAF-1/p60. The association of PARP-1 and CAF-1/p60 with the MF stage and outcome was assessed by using Fisher's exact test and Kaplan-Meier survival analysis with the Log-rank test; a p value < 0.05 was con","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-04-18T13:17:19.858Z","creation":"2022-02-10T09:45:02.497Z"},"accession":"S-EPMC8099834","cross_references":{"pubmed":["33098490"],"doi":["10.1007/s00428-020-02952-z"]}}